Publication | Closed Access

High-Dose Intravenous Immunoglobulin and Rituximab Treatment for Antibody-Mediated Rejection After Kidney Transplantation: A Cost Analysis

Transplant RejectionTransplantationKidney TransplantMedicineKidney TransplantationImmunosuppressive TherapyImmunologyRituximab TreatmentHigh-dose Intravenous ImmunoglobulinImmunotherapyTransplant ImmunologyCell TransplantationNephrologyGraft Rejection